0 shares changed hands in the last trading session. Overall, volume was down 100.00% under the stocks normal daily volume.
Investors are feeling more bearish on EnteroMedics Inc. of late as evidenced by the rise in short interest. The stock recorded a rise in short interest from September 29, 2017 to October 13, 2017 of 29.79%. Short interest grew from 1,212,447 to 1,573,645 over that timeframe. Days to cover decreased from 1.0 to 1.0 and the short interest percentage is 0.21% as of October 13.
The company is so far trading up by 3.54% percent from yesterday’s close. It is currently trading at $2.05 a bit higher than the 50 day moving average of $1.90 and impressively lower than the 200 day moving average of $3.74. The 50 day moving average was up $0.15 and the 200 day average went down $-1.69 or -45.17%.
In the last earnings report the EPS was $-6.50 and is projected to be $-1.40 for the current year with 8,294,000 shares currently outstanding. Analysts expect next quarter’s EPS to be $-0.16 and the next full year EPS is projected to be $-0.64.
EnteroMedics Inc. (EnteroMedics), launched on July 22, 2004, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Business’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to block the vagus nerve. The Business’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness..